Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Market Closed 05-08 16:00:00 EDT

16.52

+0.24

+1.47%

盘后16.52

+0.000.00%

17:10 EDT

High16.62	Low16.23	Vol1.29M
Open16.29	D1 Closing16.28	Amplitude2.43%
Mkt Cap1.71B	Tradable Cap1.43B	Total Shares103.41M
T/O21.29M	T/O Rate1.50%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":16.52,"timestamp":1778270400000,"preClose":16.28,"halted":0,"volume":1293837,"hourTrading":{"tag":"盘后","latestPrice":16.52,"preClose":16.52,"latestTime":"17:10 EDT","volume":462665,"amount":7643225.4466,"timestamp":1778274651933,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.014742014742014645,"floatShares":86361800,"shares":103405813,"eps":-3.165026,"marketStatus":"Market Closed","change":0.24,"latestTime":"05-08 16:00:00 EDT","open":16.29,"high":16.62,"low":16.225,"amount":21291507.174189,"amplitude":0.024263,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.165026,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778486400000},"marketStatusCode":7,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":16.28,"preHourTrading":{"tag":"盘前","latestPrice":16.3,"preClose":16.28,"latestTime":"08:26 EDT","volume":434,"amount":7085.930151999999,"timestamp":1778243200276,"change":0.02,"changeRate":0.001229,"amplitude":0.133907},"postHourTrading":{"tag":"盘后","latestPrice":16.52,"preClose":16.52,"latestTime":"17:10 EDT","volume":462665,"amount":7643225.4466,"timestamp":1778274651933,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.5336578807234054,"impliedVol":0.8742,"impliedVolPercentile":0.6972},"requestUrl":"/m/hq/s/NRIX/wiki","defaultTab":"wiki","newsList":[{"id":"2633797562","title":"Nurix CFO Hans van Houte disposes of common shares worth $233,463.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2633797562","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633797562?lang=en_us&edition=fundamental","pubTime":"2026-05-06 07:54","pubTimestamp":1778025261,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics CFO Hans van Houte sold 14,055 shares of common stock on May 5, 2026.Sales priced at USD 16.58 per share for 13,473 shares, USD 17.18 per share for 582 shares.Directly held stake fell to 37,592 shares following transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 05, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL4vkjss:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix CFO Hans van Houte disposes of common shares worth $233,463.29","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633964285","title":"Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205","url":"https://stock-news.laohu8.com/highlight/detail?id=2633964285","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633964285?lang=en_us&edition=fundamental","pubTime":"2026-05-05 06:11","pubTimestamp":1777932681,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring sold 8,148 shares of common stock on May 4, 2026.Sale priced at weighted average USD 16.96 per share.Directly held stake fell to 18,305 shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL9L2HPl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632512674","title":"Is Nurix’s Pan-Mutant BRAF Degrader Data Reshaping The Investment Case For Nurix Therapeutics (NRIX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2632512674","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632512674?lang=en_us&edition=fundamental","pubTime":"2026-05-03 01:38","pubTimestamp":1777743516,"startTime":"0","endTime":"0","summary":"At the April 2026 AACR Annual Meeting, Nurix Therapeutics reported new preclinical and early clinical data showing progress across its targeted protein degradation oncology pipeline, including programs aimed at pan-mutant BRAF, CBL-B, and Aurora kinase A.\nBeyond individual drug candidates, the presentations underscored how Nurix’s induced proximity and protein degradation platforms may overcome resistance and pathway limitations that challenge traditional cancer therapies.\nWith this context...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/is-nurixs-pan-mutant-braf-degrader-data-reshaping-the-invest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/is-nurixs-pan-mutant-braf-degrader-data-reshaping-the-invest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632854623","title":"Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435","url":"https://stock-news.laohu8.com/highlight/detail?id=2632854623","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632854623?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:51","pubTimestamp":1777672275,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Chief Legal Officer Christine Ring sold 5,394 shares on May 1, 2026.Sale priced at USD 16.76 per share on weighted-average basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL3d2N5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630396342","title":"Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2630396342","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630396342?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:59","pubTimestamp":1777291140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 27, 2026 07:59 ET (11:59 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629538836","title":"Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2629538836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629538836?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:41","pubTimestamp":1776944469,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. According to TipRanks, Amin ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/nurix-therapeutics-nrix-receives-a-buy-from-piper-sandler-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629835520","title":"Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2629835520","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629835520?lang=en_us&edition=fundamental","pubTime":"2026-04-23 19:21","pubTimestamp":1776943260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 07:21 ET (11:21 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629048932","title":"Nurix reports early clinical NX-1607 target engagement data at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629048932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629048932?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:07","pubTimestamp":1776856061,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics released new preclinical oncology data at AACR 2026, with results already presented in posters and an oral session.NRX-0305 showed strong anti-tumor activity in brain cancer models, including in settings resistant to existing BRAF drugs.NX-1607 demonstrated immune-activating effects in preclinical studies, with early clinical findings indicating target engagement in patients.NRX-4972 delivered better tumor control than AURKA inhibitors in an aggressive small cell lung cancer model, supporting continued development of Nurix’s degrader approach.Gwenn Hansen is scheduled to present an AACR Advances session talk later today on lessons from early clinical experience with degrader therapeutics.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLbq1Zb8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","LU2210149790.SGD","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","SG9999014039.USD","BK4588","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","SG9999014005.SGD","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","NRIX","BK4112","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629830048","title":"Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629830048","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629830048?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"Data showcase advances across oncology pipeline including pan-mutant BRAF, CBL-B and AURKA programs Presentations reinforce potential of degraders to overcome limitations of inhibitors and expand ther","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278794/0/en/Nurix-Therapeutics-Announces-New-Preclinical-Data-Highlighting-Breadth-of-Targeted-Protein-Degradation-Pipeline-at-AACR-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","PDX","CNS","BK4135","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628758416","title":"Nurix Therapeutics (NRIX) Is Up 9.2% After Reporting Sharply Lower Q1 Revenue And Wider Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2628758416","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628758416?lang=en_us&edition=fundamental","pubTime":"2026-04-18 21:05","pubTimestamp":1776517556,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics reported past first-quarter 2026 earnings, with revenue of US$6.25 million versus US$18.45 million a year earlier and a net loss of US$87.17 million versus US$56.35 million.\nThe wider basic loss per share from continuing operations, US$0.79 compared with US$0.67, highlights how the company’s cost and revenue profile has shifted year over year.\nWith these results showing sharply lower revenue, we’ll now examine how this development shapes Nurix Therapeutics’ investment...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-92-after-reporting-sharply-low","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-is-up-92-after-reporting-sharply-low","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626192831","title":"Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192831","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626192831?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:31","pubTimestamp":1775820660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2026 07:31 ET (11:31 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626819257","title":"Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Neogen (NEOG) and Nyxoah (NYXH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626819257","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626819257?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:30","pubTimestamp":1775820631,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX), Neogen (NEOG) and Nyxoah ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nurix-therapeutics-nrix-neogen-neog-and-nyxoah-nyxh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nurix-therapeutics-nrix-neogen-neog-and-nyxoah-nyxh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","BK4137","BK4581","BK4585","BK4139","BK4082","LU0029874061.USD","LU2211817866.USD","XLV","HCSG","NEOG","NRIX","XBI","LABU","LU0128526141.USD","BK4588","NYXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626762132","title":"Nurix Therapeutics Inc reports results for the quarter ended February 28 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2626762132","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626762132?lang=en_us&edition=fundamental","pubTime":"2026-04-10 03:02","pubTimestamp":1775761373,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Inc reports results for the quarter ended February 28 - Earnings SummaryNurix Therapeutics Inc NRIX.OQ reported a quarterly adjusted loss of 79 cents per share for the quarter ended","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL8N40S227:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626929182","title":"Nurix Therapeutics price target lowered to $34 from $35 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2626929182","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626929182?lang=en_us&edition=fundamental","pubTime":"2026-04-09 01:40","pubTimestamp":1775670047,"startTime":"0","endTime":"0","summary":"Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $35 and keeps a Buy rating on the shares after the company reported...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-lowered-to-34-from-35-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-lowered-to-34-from-35-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626275926","title":"Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2626275926","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626275926?lang=en_us&edition=fundamental","pubTime":"2026-04-09 01:28","pubTimestamp":1775669280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 13:28 ET (17:28 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626926991","title":"Nurix Therapeutics: Buy Rating Backed by Advancing Bexobrutideg Program, Sanofi STAT6 Milestones, and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2626926991","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626926991?lang=en_us&edition=fundamental","pubTime":"2026-04-09 01:15","pubTimestamp":1775668520,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nurix-therapeutics-buy-rating-backed-by-advancing-bexobrutideg-program-sanofi-stat6-milestones-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nurix-therapeutics-buy-rating-backed-by-advancing-bexobrutideg-program-sanofi-stat6-milestones-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SNYNF","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625942348","title":"Nurix Therapeutics Shares up 3% After Q1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2625942348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625942348?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:35","pubTimestamp":1775655359,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL4N40R18E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625941891","title":"Nurix Therapeutics Q1 EPS $(0.79) Beats $(0.86) Estimate, Sales $6.252M Miss $16.607M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2625941891","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625941891?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:42","pubTimestamp":1775652120,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.86) by 8.14 percent. This is a 17.91 percent decrease over losses of $(0.67) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/51701493/nurix-therapeutics-q1-eps-0-79-beats-0-86-estimate-sales-6-252m-miss-16-607m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917746","title":"Nurix Therapeutics Shares Trim Premarket Gains After Q1 Results, Last up 3.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625917746?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:10","pubTimestamp":1775643028,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nFWN40Q1GA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NRIX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917774","title":"Nurix Therapeutics Q1 loss widens on higher costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917774","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625917774?lang=en_us&edition=fundamental","pubTime":"2026-04-08 18:09","pubTimestamp":1775642986,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Q1 loss widens on higher costsOverviewUS biopharmaceutical firm's fiscal Q1 revenue fell sharply yr/yr as collaboration revenue declinedOperating expenses for fiscal Q1 rose, driven","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nL1N40R0CG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","IE00B19Z3B42.SGD","LU0170899867.USD","LU0321505439.SGD","LU0965508806.USD","NRIX","LU0320765992.SGD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","SG9999015952.SGD","LU0965509283.SGD","LU0109394709.USD","SG9999015978.USD","SG9999002224.SGD","LU1674673691.USD","BK4583","SGXZ57979304.SGD","LU1037948541.HKD","LU1571399168.USD","LU2468319806.SGD","LU0456855351.SGD","SG9999003800.SGD","LU0868494617.USD","IE00BBT3K403.USD","IE00B3T34201.USD","SG9999001176.SGD","LU1883839398.USD","IE00BLSP4239.USD","LU1037948897.HKD","LU2112291526.USD","LU1934455194.USD","IE00BKVL7J92.USD","LU2324357040.USD","LU0058720904.USD","SG9999011175.SGD","IE00BLSP4452.SGD","SG9999013999.USD","BK4592","BK4585","SG9999015986.USD","LU1934455277.USD","LU1778281490.HKD","LU0985481810.HKD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0861579265.USD","LU0882574055.USD","BK4581","LU1057294990.SGD","BK4550","LU1934455863.HKD","BK4139","BK4533","IE000M9KFDE8.USD","LU0234572021.USD","SG9999002232.USD","LU0965509010.AUD","LU0122379950.USD","LU1066053197.SGD","LU0306806265.USD","LU2089984988.USD","SG9999001176.USD","IE00BZ1G4Q59.USD","LU1061106388.HKD","LU0114720955.EUR","LU0823416689.USD","IE0002270589.USD","BK4578","BK4532","LU1674673428.USD","LU1585245621.USD","LU2087621335.USD","LU1894683264.USD","LU1023059063.AUD","BK4599","LU0965509101.SGD","LU0289739699.SGD","SG9999015945.SGD","BK4566","LU0889565916.HKD","BK4568","BK4588","LU0306807586.USD","IE00B19Z3581.USD","LU0225771236.USD","IE00BSNM7G36.USD","LU1839511570.USD","BK4007","BK4534"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.0173},{"period":"1month","weight":0.059},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.342},{"period":"1year","weight":0.7137},{"period":"ytd","weight":-0.1292}],"compareEarnings":[{"period":"1week","weight":0.0235},{"period":"1month","weight":0.0911},{"period":"3month","weight":0.0681},{"period":"6month","weight":0.0993},{"period":"1year","weight":0.3054},{"period":"ytd","weight":0.0817}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.166667,"avgChangeRate":-0.011931},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.064842},{"month":4,"riseRate":0.5,"avgChangeRate":-0.023295},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.002483},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction